Warner–Lambert

Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives

Retrieved on: 
Wednesday, January 3, 2024

IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.

Key Points: 
  • IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.
  • More information on this state-of-the-art formulation of Botulinum toxin will be provided once regulatory approvals are obtained.
  • In connection with the formation of Luvantas, Thomas A. Albright has been appointed its President and CEO and Stephanie A. Yee has been appointed its CFO.
  • As CEO, Tom brings 40 years of healthcare experience to Luvantas with medical aesthetic leadership roles since 2000.

INW Appoints Ray Eby as Chief Executive Officer and Paul Sturman as Executive Chairman

Retrieved on: 
Thursday, June 29, 2023

FARMINGTON, Utah, June 29, 2023 /PRNewswire/ -- INW, a market leading manufacturer of nutrition and wellness products, is excited to announce the appointment of Ray Eby as its Chief Executive Officer, effective July 1st.

Key Points: 
  • FARMINGTON, Utah, June 29, 2023 /PRNewswire/ -- INW, a market leading manufacturer of nutrition and wellness products, is excited to announce the appointment of Ray Eby as its Chief Executive Officer, effective July 1st.
  • Ray will be joining INW after an 18-year career at 3M where he has extensive operational, M&A and corporate experience.
  • Ray previously held leadership roles in 3M's Consumer Health, Tapes and Closure, Automotive, and Safety and Security businesses.
  • Under the ownership and guidance of Cornell Capital, INW has also welcomed Paul Sturman, as Executive Chairman of the INW Board of Directors.

Kraft Heinz Announces Humberto Alfonso as New Independent Board Member

Retrieved on: 
Thursday, May 4, 2023

The Kraft Heinz Company (Nasdaq: KHC) (“Kraft Heinz” or “the Company”) announced today that Humberto “Bert” Alfonso has been elected to join the Board of Directors (“Board”), effective May 4, 2023.

Key Points: 
  • The Kraft Heinz Company (Nasdaq: KHC) (“Kraft Heinz” or “the Company”) announced today that Humberto “Bert” Alfonso has been elected to join the Board of Directors (“Board”), effective May 4, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230504005754/en/
    “The Board is pleased with the election of Bert Alfonso, current Executive Vice President and Chief Financial Officer of Information Services Group, Inc.,” said Miguel Patricio, Chief Executive Officer, and Chair of the Board of Directors of Kraft Heinz.
  • Alfonso has served on the Board of Directors of Eastman Chemical Company, a specialty chemical company, since 2011 and previously served on the Board of Directors of Yowie Group from 2017 to 2018.
  • "I am honored to join the Kraft Heinz Board,” said Alfonso.

ACG appoints Rafael Costa as Vice President Sales for the Americas Region

Retrieved on: 
Monday, February 6, 2023

MUMBAI, India, Feb. 6, 2023 /PRNewswire/ -- ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce the appointment of Rafael Costa as Vice President for the Americas region.

Key Points: 
  • MUMBAI, India, Feb. 6, 2023 /PRNewswire/ -- ACG, a leading supplier of fully integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce the appointment of Rafael Costa as Vice President for the Americas region.
  • In his new role, Rafael Costa will be responsible for leading sales and business development in North and South America for Capsules and Vantage Nutrition.
  • With almost 30 years' experience working across the pharmaceutical and nutraceutical sectors within the Americas region, Rafael Costa has led numerous companies in different markets in both North and South America, including business Integrations.
  • Selwyn Noronha, CEO of ACG Capsules, said: "We are delighted that Rafael has decided to join ACG.

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Retrieved on: 
Tuesday, January 17, 2023

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.
  • Mr. Zayas will be responsible for all of the company’s North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland.
  • He will serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
  • View the full release here: https://www.businesswire.com/news/home/20230117005260/en/
    Ricardo Zayas, who joins Catalent as Senior Vice President, Operations, Biologics North America.

Niron Magnetics Expands Management Team with Three Key Technology and Operations Hires

Retrieved on: 
Wednesday, September 28, 2022

All three are talented, growth-oriented experts in their respective fields with experience scaling global materials companies, said Andy Blackburn, CEO of Niron Magnetics.

Key Points: 
  • All three are talented, growth-oriented experts in their respective fields with experience scaling global materials companies, said Andy Blackburn, CEO of Niron Magnetics.
  • Nirons mission and the world changing potential of our technology is what attracted these new team members to join us.
  • Their passion and expertise further empower our team as we usher in a more sustainable future for the magnetics industry.
  • Peter Ladwig, Ph.D., vice president, nanoparticle technology joins Niron following nearly 20 years with TDK Hutchinson Technology.

Dr. Miranda Orr Wins Alzheimer's Drug Discovery Foundation's Prestigious Melvin R. Goodes Prize

Retrieved on: 
Thursday, September 22, 2022

NEW YORK, Sept. 22, 2022 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has named Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, as the recipient of the 2022 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development. The annual award includes $150,000 and will support Dr. Orr's pioneering work targeting senescent cells to translate the biology of aging into effective treatments for Alzheimer's disease.

Key Points: 
  • NEW YORK, Sept. 22, 2022 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) has named Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, as the recipient of the 2022 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development.
  • The Melvin R. Goodes Prize is named in honor of the courage, legacy and research advocacy of Mr. Goodes, former Warner-Lambert CEO and Chairman and honorary member of the ADDF's Board of Governors.
  • It was created thanks to the generosity of Mr. Goodes and his wife, Nancy, who is also on the ADDF's Board.
  • The Goodes Family Foundation committed $750,000 to fund the Goodes Prizes for 10 years, and the ADDF matched that contribution.

OcyonBio Appoints Ricardo Zayas as Chief Operating Officer

Retrieved on: 
Monday, February 14, 2022

AGUADILLA, Puerto Rico, Feb. 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Ricardo Zayas its Chief Operating Officer.

Key Points: 
  • AGUADILLA, Puerto Rico, Feb. 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Ricardo Zayas its Chief Operating Officer.
  • Ricardo Zayas was most recently Executive Vice President and Head of Operations for Romark Global Pharma, LLC.
  • I am proud to help develop this expertise in Puerto Rico," stated Ricardo Zayas, COO.
  • OcyonBio provides a company with its own space, so there is no need to build an expensive facility.

MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments

Retrieved on: 
Monday, February 7, 2022

MEI Pharma has made significant strides in its progress toward becoming a commercial stage company, said Dr. Ricart.

Key Points: 
  • MEI Pharma has made significant strides in its progress toward becoming a commercial stage company, said Dr. Ricart.
  • Ms. Gomez-Naiden joins MEI with over 25 years of experience in both biotechnology and pharmaceutical industries, and her expertise spans quality assurance operations, quality systems, integrations, regulatory compliance and quality management.
  • Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma, commented, "We are very excited by the recent appointments of Dr. Ricart and Ms. Gomez-Naiden, strengthening our clinical and quality functions.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.

Dr. Sangtae Kim to Lead Verseon's New AI and Data-Science Initiative as CTO

Retrieved on: 
Wednesday, January 12, 2022

FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.

Key Points: 
  • FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.
  • Sang, a member of the US National Academy of Engineering , will spearhead expansion of the company's data-science and AI initiatives.
  • Sang's engineering and data-science expertise will both complement and expand Verseon's already significant technological advantages in computer-driven drug design.
  • In recent years he has started research initiatives to use AI for multiple aspects of drug design and development.